Aviatrix Announces 10,000th “Aviatrix Certified Engineer” (ACE) Milestone and Introduces New Multi-Cloud Network Operations Certification
16.2.2021 17:00:00 EET | Business Wire | Press release
Aviatrix, the cloud network platform, today announced it has reached yet another significant milestone with its Aviatrix Certified Engineers (ACE) Program, while also launching a new multi-cloud network operations curriculum that builds on the basic cloud networking knowledge required to achieve ACE Multi-Cloud Networking Associate certification. The designation ACE Multi-Cloud Network Operations validates a cloud networking professional’s ability to successfully operate and manage multi-cloud networking and security services that support their organization’s needs. This course also introduces CI/CD and Infrastructure-as-a-Code (IaC) concepts, as more innovative solutions for operating cloud networking and security. Automation tools such as Terraform and the Aviatrix multi-cloud Terraform provider help operations an DevOps teams work closely together to deploy a repeatable and auditable infrastructure, leveraging a single CI/CCD pipeline.
With over 10,000 ACEs representing more than 2,500 companies, in over 110 countries worldwide, the Aviatrix ACE Program is the leading and most recognized multi-cloud networking technical certification. Specifically, this training program has helped cloud networking professionals and their companies close the skills gap, learn basic cloud service provider (CSP) constructs and how to add value by learning best practices for multi-cloud network architectures.
“Cloud networking is important but is also very complex. The Aviatrix ACE Program allows me to better understand the designs and limitations of all major cloud service providers (AWS, Azure, GCP, OCI, etc.,). This valuable education also helps architects and engineers design and build enterprise-class cloud networking solutions that meet enterprise-class security, performance, and compliance requirements. I strongly recommend this program to anyone interested in learning more about Hybrid or Multi-Cloud networking,” exclaimed Walter Lee, Sr. Software Engineer, at a leading global financial services company.
The ACE Program helps prepare an organization’s technical staff to lead and accelerate their transformation to cloud. The program is the first multi-cloud networking and security certification available to cloud practitioners, DevOps, networking staff, and security professionals. The ACE certification is designed for individuals who understand basic networking concepts and prepares engineers and operations staff with knowledge on (1) native cloud networking constructs in AWS, Azure, Google Cloud, and Oracle Cloud Infrastructure and (2) multi-cloud design patterns and concepts and (3) proficiency to plan and provision multi-cloud network use cases and architecture using the Aviatrix cloud network platform.
“The industry demand for the ACE Program over the past 12 months continues to exceed our expectations,” said Nauman Mustafa, Vice President Solutions Engineering, at Aviatrix. “With ACE, we provide the required training cloud networking professionals need to fully understand public-cloud networking constructs, service provider capabilities, different multi-cloud architectural design patterns, and how to apply this knowledge to their specific environment. Furthermore, our newly launched multi-cloud network operations course will enable the ACEs to successfully run, operate and efficiently manage their business-critical workloads in the cloud. They will also gain greater visibility, observability, and monitoring capabilities that go well beyond the basic operations and troubleshooting tools they get from their CSPs.”
Join the ACE Community Today!
To learn more about the ACE program, including the schedule for self-paced and instructor-led courses, course curriculum and other details, visit https://aviatrix.com/ace/. Or email us at ace@aviatrix.com to request more information.
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005239/en/
Contact information
PR Contact:
Aviatrix
Dmitry Lipkin
dlipkin@aviatrix.com
408-888-2792
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom